CBS 2019
CBSMD教育中心
English

Transcatheter Aortic Valve Replacement

科研文章

荐读文献

Anticoagulation After Surgical or Transcatheter Bioprosthetic Aortic Valve Replacement Left ventricular remodelling and changes in functional measurements in patients undergoing transcatheter vs surgical aortic valve replacement: a head-to-head comparison Long-Term Outcomes of Anticoagulation for Bioprosthetic Valve Thrombosis Long-term outcome of prosthesis-patient mismatch after transcatheter aortic valve replacement von Willebrand Factor and Management of Heart Valve Disease: JACC Review Topic of the Week Impact of Pre-Existing and New-Onset Atrial Fibrillation on Outcomes After Transcatheter Aortic Valve Replacement Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic Severe Bicuspid Aortic Valve Stenosis Aortic Valve Stenosis Treatment Disparities in the Underserved JACC Council Perspectives Frailty in Older Adults Undergoing Aortic Valve Replacement: The FRAILTY-AVR Study Discrepancies in Measurement of the Thoracic Aorta: JACC Review Topic of the Week

EditorialMay 2, 2019

JOURNAL:N Engl J Med. Article Link

Informed Shared Decisions for Patients with Aortic Stenosis

CM Otto. Keywords: symptomatic aortic stenosis; TAVR; SAVR;

First 100 Words


Valve replacement is the only effective treatment for adults with severe, symptomatic aortic stenosis. The ideal prosthetic valve would be associated with minimal risk and discomfort at implantation, would have hemodynamics similar to those of a normal valve, would not require anticoagulation, and would be durable for the patient’s lifetime. We are moving closer to this goal, as evidenced by sequential randomized clinical trials of transcatheter aortic-valve replacement (TAVR), initially in patients at prohibitive or high estimated risk for death with surgical aortic-valve replacement, then in patients at intermediate risk, and now — in the trials by Mack et al.